A Fatal Case of Pembrolizumab-Induced Myocarditis in Non–Small Cell Lung Cancer

Max Cohen, BS; Saim Mustafa, BA; Islam Elkherpitawy, MD; Matthew Meleka, DO

JACC: Case Reports (Mar 2020)

A Fatal Case of Pembrolizumab-Induced Myocarditis in Non–Small Cell Lung Cancer

Max Cohen, BS,
Saim Mustafa, BA,
Islam Elkherpitawy, MD,
Matthew Meleka, DO

Affiliations

Max Cohen, BS: New York Institute of Technology College of Osteopathic Medicine, Glen Head, New York; Address for correspondence: Mr. Max Cohen, New York Institute of Technology College of Osteopathic Medicine, 2090 East 22nd Street, Brooklyn, New York 11229.
Saim Mustafa, BA: Lake Erie College of Osteopathic Medicine, Erie, Pennsylvania
Islam Elkherpitawy, MD: Jersey Shore University Hospital and Medical Center, Neptune, New Jersey
Matthew Meleka, DO: Jersey Shore University Hospital and Medical Center, Neptune, New Jersey

Journal volume & issue: Vol. 2, no. 3
pp. 426 – 430

Abstract

Read online

Immune channel inhibitor–induced myocarditis is rare, and its management is challenging. Recently, guidelines were established for all ICIs, yet they do not take into account individual drug toxicities or screening protocols for prevention. We present a rare case of rapidly progressive pembrolizumab-induced fatal myocarditis in an initially asymptomatic patient. (Level of Difficulty: Beginner.)

Published in JACC: Case Reports

ISSN: 2666-0849 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://www.journals.elsevier.com/jacc-case-reports

About the journal

Abstract

Keywords